SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ:ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased enGene securities?
If you purchased enGene securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On May 7, 2026, enGene announced updated interim results from the pivotal cohort of its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Among other things, enGene disclosed that patients ...
Comments (0)
Be the first to leave a comment on this story.